TP53 loss-of-function mutations were associated with increased LC3B, ULK1 and BECLIN1 expression in CRPC tumour specimens. Androgen-independent tumour organoids were highly vulnerable to CQ or ULK101 in combination with enzalutamide. Here, TP53 is linked to neoplasm.